Drug Profile
Research programme: autologous adult stem cell-based therapies - osteoporosis and bone regeneration - Lisata Therapeutics/University of Michigan
Latest Information Update: 19 Sep 2022
Price :
$50
*
At a glance
- Originator NeoStem; University of Michigan
- Developer Lisata Therapeutics; University of Michigan
- Class Stem cell therapies
- Mechanism of Action Bone development stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bone disorders; Osteoporosis; Periodontitis
Most Recent Events
- 14 Sep 2022 Cend Therapeutics has merged with Caladrius Biosciences to form Lisata Therapeutics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Periodontitis in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-disorders in USA (Parenteral)